Attached files
| file | filename |
|---|---|
| 8-K - Altimmune, Inc. | v200482_8k.htm |
| EX-5.1 - Altimmune, Inc. | v200482_ex5-1.htm |
| EX-1.1 - Altimmune, Inc. | v200482_ex1-1.htm |
| EX-1.2 - Altimmune, Inc. | v200482_ex1-2.htm |
| EX-99.2 - Altimmune, Inc. | v200482_ex99-2.htm |
PharmAthene
Announces Proposed Common Stock Public Offering
ANNAPOLIS,
Md., October 28, 2010 /PRNewswire via COMTEX/ —
PharmAthene,
Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures
against biological and chemical threats, today announced that it intends to
offer and sell shares of its common stock in an underwritten public offering.
The offering is subject to market conditions and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or terms
of the offering. Roth Capital Partners, LLC. is acting as sole underwriter for
the offering.
The
shares are being offered by PharmAthene pursuant to a shelf registration
statement previously filed with and declared effective by the Securities and
Exchange Commission (“SEC”) on February 13, 2009. A preliminary prospectus
supplement relating to the offering will be filed with the SEC and will be
available on the SEC’s website located at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to this offering
may be obtained from Roth Capital Partners, LLC Syndicate
Department, 24 Corporate Plaza, Newport Beach, CA 92660, at
800-678-9147 and Rothecm@roth.com. Before you invest, you should read the
prospectus and prospectus supplement in that registration statement and other
documents PharmAthene has filed or will file with the SEC for more complete
information about PharmAthene and the offering.
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such
jurisdiction.
Statement
on Cautionary Factors
Except
for the historical information presented herein, matters discussed may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including statements
preceded by, followed by, or that include the words "potential"; "believe";
"anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should";
"will"; "project"; "potential"; or similar statements are forward-looking
statements. PharmAthene disclaims any intent or obligation to update these
forward-looking statements other than as required by law. Risks and
uncertainties include risk associated with the reliability of the results of the
studies relating to human safety and possible adverse effects resulting from the
administration of the Company's product candidates, unexpected funding delays
and/or reductions or elimination of U.S. government funding for one or more of
the Company's development programs, the award of government contracts to our
competitors, unforeseen safety issues, challenges related to the development,
scale-up, technology transfer, and/or process validation of manufacturing
processes for our product candidates, unexpected determinations that these
product candidates prove not to be effective and/or capable of being marketed as
products, challenges related to the implementation of our NYSE Amex compliance
plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K
and 10-Q under the caption "Risk Factors" and in its other reports filed with
the U.S. Securities and Exchange Commission (the "SEC"). In particular, there
can be no assurance that PharmAthene will satisfy the NYSE Amex continuing
listing standards by January 26, 2012, or that during the compliance period the
Exchange will not deem PharmAthene's progress toward compliance inadequate. In
either case, the NYSE Amex may immediately initiate delisting
proceedings.
Copies of
PharmAthene's public disclosure filings are available from its investor
relations department and our website under the investor relations tab at
www.PharmAthene.com.
- 2
-